Development of Mebeverine HCl Prolonged release Mini-tablets by thermoplastic granulation technique
Abstract
Mebeverine HCl is a BCS class-I drug and thus it possesses high solubility in aqueous media across the biological pH range. The marketed reference product is a multi-unit particulate system (MUPS) containing prolonged release pellets filled in hard gelatin capsule. In conventional manufacturing process, a huge quantity of solvents (aqueous and/or organic) is used to manufacture such dosage form. Additionally, it demands more processing time and efforts. Therefore, a prolonged release capsules dosage form of Mebeverine HCl was formulated using thermoplastic (melt) granulation technique without usage of any solvent. Prolonged release minitablets sized 2 mm in diameter were developed as per quality by design principles. A 23 full-factorial design of experiment was applied to optimize levels of drug release controlling ingredients which includes a hydrophobic meltable binder (hydrogenated castor oil) cum matrixing agent, a hydrophilic meltable binder (polyethylene glycol) which may act as pore former also, and a release controlling polymer (ethyl cellulose). The optimized formulation was found stable. Dissolution profiles of the optimized formulation were found similar to the marketed reference product in different media across the physiological pH range. In conclusion, the explored solvent less process was capable to manufacture the MUPS dosage form of Mebeverine HCl prolonged-release capsules, which is stable and pharmaceutically equivalent with the reference product. The developed process is more beneficial to small and medium scale industry, as it does not require any special and costly equipment, significantly decreases manufacturing cost and increases productivity compared to conventional process, which is mentioned in literature.
Keywords:
Melt Granulation, thermoplastic granulation, Solvent-free process, Mebeverine, Mini-tabletsDOI
https://doi.org/10.25004/IJPSDR.2020.120308References
Pharmaceutical Pellets Market is Showing Rapid Growth, Worldwide : Forecast 2019-2026 [Internet]. Gurufocus. 2019 [cited 2020 Feb 3]; https://www.gurufocus.com/news/980947/pharmaceutical-pellets-market-is-showing-rapid-growth-worldwide--forecast-20192026
Sirisha KV, Vijaya SK, Suresh K, Reddy G, Devanna N. A review of pellets and pelletization process – a multiparticulate drug delivery system. IJPSR. 2013; 4(6):2145-2158.
Yadav N, Verma A. Pharmaceutical Pellets: A Versatile Carrier for Oral Controlled Delivery of Drugs. IJPER. 2016; 50(3):146-160.
Colofac MR 200 mg Modified Release Capsules - Summary of Product Characteristics (SmPC) - (emc) [Internet]. 2016 [cited 2020 Feb 9]: https://www.medicines.org.uk/emc/product/5526#EXCIPIENTS
Mandel KG, Sheldon RJ. Mebeverine dosage form [Internet]. 1990 [cited 2020 Feb 3]; https://patents.google.com/patent/EP0393747A2/en
Gandhi R, Lal KC, Panchagnula R. Extrusion and spheronization in the development of oral controlled-release dosage forms. Pharmaceutical Science & Technology Today. 1999; 2(4):160-70.
Desai U, Chaudhari P, Bhavsar D, Chavan R. Melt granulation: An alternative to traditional granulation techniques. Indian Drugs. 2013; 50:5-13.
Wong T, Cheong W, Hang P. Melt Granulation and Pelletization: Handbook of Pharmaceutical Granulation Technology. Taylor & Francis Group, 2005. page 385-406.
Becker K, Salar-Behzadi S, Zimmer A. Solvent-Free Melting Techniques for the Preparation of Lipid-Based Solid Oral Formulations. Pharm Res. 2015; 32(5):1519-1545.
Maejima T, Kubo M, Osawa T, Nakajima K, Kobayashi M. Application of Tumbling Melt Granulation (TMG) Method to Prepare Controlled-Release Fine Granules. Chem Pharm Bull. 1998; 46(3):534-536.
Yang D, Kulkarni R, Behme R, Kotiyan P. Effect of the melt granulation technique on the dissolution characteristics of griseofulvin. International Journal of Pharmaceutics. 2007; 329(1–2):72-80.
Gupta S, Munjal T, Kaur A, Bagga KS. Fabrication and characterization of Cefopodoxime proxetil solid dispersion for solubility enhancement. Int J Pharm Sci Drug Res. 2014; 6(4):271-277.
Singh I, Kumar P, Rani N, Rana V. Investigation of different lipid based materials as matrices designed to control the release of a hydrophobic drug. Int J Pharm Sci Drug Res 2009;1(3):158-63.
Shah SK, Bhudholiya P, Pandey S, Kushwaha S, Khan F. Design of Extended Release Matrix Tablet of Tramadol hydrochloride Using Combination of Hydrophobic and Hydrophilic Polymer. IJPSDR. 2017; 9(05):214-215.
Campisi B, Vojnovic D, Chicco D, Phan-Tan-Luu R. Melt granulation in a high shear mixer: optimization of mixture and process variables using a combined experimental design. Chemometrics and Intelligent Laboratory Systems. 1999; 48(1):59-70.
Kothapelly R, Nalluri LP, Gaddam V, Rachawar NK, Akuthota AK. UV spectrophotometric method development and validation for the simultaneous quantitative estimation of Mebeverine hydrochloride and Chlordiazepoxide in capsules. International Journal of Pharmacy and Pharmaceutical Sciences. 2014; 6(8):345-349.
Petchimuthu S, Narayanan N, Uthirapathy S. Formulation of mebeverine hydrochloride MR pellets in capsules and comparative characterization against colofac MR capsules. International Journal of Pharmacy and Analytical Research. 2014; 3(4):348-362.
ICH Official web site. [Internet]. [cited 2020 Feb 9]; http://database.ich.org/sites/default/files/Q1A%28R2%29%20Step4.pdf
Bioavailability studies submitted in NDA or INDs - General considerations: Appendix C: Guidelines for conducting in-vitro alcohol dose-dumping study [Internet]. 2019 [cited 2020 Feb 9]; https://www.fda.gov/media/121311/download
Friebe TP, Asgarzadeh F, Gray A, Hughes K, Hebestreit JP, Rosiaux Y, et al. Regulatory Considerations for Alcohol-Induced Dose Dumping of Oral Modified-Release Formulations. Pharmaceutical Technology. 2015; 38(10):40-46.
Mandel KG, Sheldon RJ. Mebeverine dosage form [Internet]. 1990 [cited 2020 Feb 9]; https://patents.google.com/patent/EP0393747A2/en
Published
Abstract Display: 1165 
PDF Downloads: 782 
